Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Investing in the Best Canadian Biotech Stocks

Equities.com June 23, 2014

Tekmira Initiating Phase I/II Clinical Trial in Patients with Hepatocellular Carcinoma

GlobeNewswire May 27, 2014

Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs

GlobeNewswire May 21, 2014

Tekmira Provides Corporate Update and Announces First Quarter 2014 Results

GlobeNewswire May 14, 2014

Tekmira Reports on Voting Results From 2014 Annual Meeting of Shareholders

GlobeNewswire May 9, 2014

Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results

GlobeNewswire May 7, 2014

Tekmira's Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02)

GlobeNewswire April 28, 2014

Tekmira Pharmaceuticals (T.TKM) CTO presents anti-viral product platform at symposium

Gaalen Engen April 1, 2014

Tekmira Presents Advances in Anti-Viral Product Platform at Scientific Symposium

GlobeNewswire April 1, 2014

Tekmira Announces Completion of Underwritten Public Offering of Common Stock

GlobeNewswire March 18, 2014

Tekmira Announces Pricing of Underwritten Public Offering of Common Stock

GlobeNewswire March 13, 2014

Tekmira Announces Proposed Public Offering of Common Stock

GlobeNewswire March 10, 2014

Tekmira Provides Corporate Update and Announces Year-End 2013 Results

GlobeNewswire March 6, 2014

Tekmira Receives Fast Track Designation From FDA for Its Anti-Ebola Viral Therapeutic

GlobeNewswire March 5, 2014

Tekmira Conference Call and Webcast Advisory: Corporate Update and 2013 Year-End Financial Results

GlobeNewswire March 4, 2014

Tekmira Pharmaceuticals (T.TKM) pops 12% on presenting mRNA delivery advances

Gaalen Engen February 25, 2014

Tekmira Presents Recent Advances in mRNA Delivery at Scientific Symposium

GlobeNewswire February 25, 2014

Tekmira Announces Filing of Shelf Prospectus and Registration Statement

GlobeNewswire February 21, 2014

Webcast Advisory: Tekmira to Present at the 2014 RBC Capital Markets' Global Healthcare Conference

GlobeNewswire February 20, 2014

Tekmira Announces New Appointment to Board of Directors

GlobeNewswire February 12, 2014